AUS
NZ
UK
CA
USA
IND
Highlights
- Imugene begins Phase II patient dosing for colorectal cancer immunotherapy
- Neo-POLEM study explores pre-surgery treatment with PD1-Vaxx
- Trial targets mismatch repair-deficient colorectal cancer subtype
In a significant development for cancer immunotherapy, Imugene Ltd (ASX:IMU) has announced the initiation of patient dosing in its Phase II Neo-POLEM clinical trial. The study investigates PD1-Vaxx, an innovative B-cell immunotherapy vaccine, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-high) colorectal cancer. The first patient received treatment at Queen Elizabeth Hospital in Adelaide, marking a key milestone for the company’s clinical pipeline.
Exploring New Frontiers in Cancer Immunotherapy
The Neo-POLEM trial is a neoadjuvant study, meaning the PD1-Vaxx treatment is given before surgery. This approach aims to improve patient outcomes by priming the immune system early against cancer. dMMR/MSI-high colorectal cancer affects roughly 15% of colorectal cancer patients, making it a notable target for pre-surgical immunotherapy. Recruitment is underway across multiple locations in Australia and the United Kingdom.
Imugene’s broader pipeline includes several promising assets beyond PD1-Vaxx, such as the CF33 oncolytic virotherapy and a ready-to-use CAR T-cell therapy targeting CD19 in blood cancers. These programs align with the company’s mission to empower the immune system to combat cancer across various tumor types.
Trial Design and Objectives
The Phase II study is being conducted as an Investigator Sponsored Trial in collaboration with research institutions in both the UK and Australia. The primary focus is to evaluate the major pathological response—essentially how much the tumor shrinks after vaccination. Additional objectives include assessing safety, identifying predictive biomarkers, and measuring long-term patient outcomes.
This trial expands on earlier research suggesting immunotherapy may provide considerable benefits for dMMR/MSI-high colorectal cancer cases. By targeting the cancer at its early stages, PD1-Vaxx seeks to increase the effectiveness of surgical treatment and potentially improve survival rates.
Relevance Within the ASX Landscape
While Imugene is not currently part of the ASX 200, the company continues to be a focus of innovation within the Australian biotech sector. Its progress in immunotherapy and early-stage clinical success highlights its growing relevance within the broader ASX-listed healthcare landscape.
The Global Significance
Globally, colorectal cancer remains the third most diagnosed cancer, with more than 1.2 million new cases annually. With around 80% of cases being surgically resectable at diagnosis, the integration of immunotherapy before surgery may offer a strategic advantage in managing this disease. Imugene’s continued efforts reflect a broader trend toward personalising and enhancing cancer care through immune-based interventions.
As the Neo-POLEM trial progresses, the results could offer a new treatment paradigm for a subgroup of colorectal cancer patients, strengthening Imugene’s footprint in the immuno-oncology space.
